Efficacy and safety outcomes of multiple procedure follow-up
| Total | BMI<30 | BMI≥30 | P values | |
| Total n, PVI median (range) | 2.0 (1–5) | 2.0 (1–4) | 2.0 (1–5) | 0.505 |
| Multiple procedure success | ||||
| 12 months FU no AAD, n (%) | 119 (29%) | 93 (31%) | 26 (23%) | 0.178 |
| 12 months with and without AAD, n (%) | 221 (53%) | 163 (54%) | 58 (52%) | 0.911 |
| Long-term FU no AAD, n (%) | 172 (42%) | 139 (46%) | 33 (30%) | 0.005 |
| Long-term FU with and without AAD, n (%) | 268 (65%) | 206 (68%) | 62 (56%) | 0.036 |
| Major adverse events | ||||
| Procedure-related death | 0 | 0 | 0 | |
| Cardiac tamponade/perforation | 9 | 5 | 4 | |
| Thromboembolic event | 4 | 2 | 2 | |
| Air-embolic event | 2 | 2 | 1 | |
| Total (multiple procedures) | 16 (4%) | 9 (3%) | 7 (6%) | 0.105 |
| Minor adverse events | ||||
| Femoral bleeding/aneurysm/AVF | 14 | 9 | 5 | |
| Pericardial effusion no intervention | 4 | 3 | 1 | |
| Phrenic nerve lesion | 1 | 1 | 0 | |
| Pulmonary vein stenosis (asymptomatic) | 1 | 1 | 0 | |
| Pericarditis | 1 | 1 | 0 | |
| Total (multiple procedures) | 21 (5%) | 15 (5%) | 6 (5%) | 0.512 |
| Major or minor adverse events (multiple procedures) | 37 (9%) | 24 (8%) | 13 (12%) | 0.158 |
AAD, antiarrhythmic drugs; AVF, arterial venous fistula; BMI, body mass index; FU, follow-up; PVI, pulmonary vein isolation.